ClinVar Miner

Submissions for variant NM_000059.4(BRCA2):c.9502-12T>G (rs81002803)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 12
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Evidence-based Network for the Interpretation of Germline Mutant Alleles (ENIGMA) RCV000114123 SCV001161603 benign Breast-ovarian cancer, familial 2 2019-06-18 reviewed by expert panel curation IARC class based on posterior probability from multifactorial likelihood analysis, thresholds for class as per Plon et al. 2008 (PMID: 18951446). Class 1 based on posterior probability = 4.00E-07
Invitae RCV000045842 SCV000073855 benign Hereditary breast and ovarian cancer syndrome 2019-12-31 criteria provided, single submitter clinical testing
Ambry Genetics RCV000131584 SCV000186594 likely benign Hereditary cancer-predisposing syndrome 2020-01-16 criteria provided, single submitter clinical testing RNA Studies;Subpopulation frequency in support of benign classification
GeneDx RCV000589086 SCV000210509 uncertain significance not provided 2018-11-05 criteria provided, single submitter clinical testing This variant is denoted BRCA2 c.9502-12T>G or IVS25-12T>G and consists of a T>G nucleotide substitution at the -12 position of intron 25 of the BRCA2 gene. In silico analysis, which includes splice predictors and evolutionary conservation, supports a deleterious effect. While an mRNA analysis suggested this variant causes loss of the nearby splice acceptor site, leading to deletion of exon 26 and a non-functional protein (Joosse 2012), an RT-PCR mini-gene assay detected only weak effects on splicing (Acedo 2015). This variant, also denoted as 9730-12T>G using alternate nomenclature, has been observed in at least four individuals with a personal or family history of breast and/or ovarian cancer (Vehmanen 1997, Levanat 2012, Tea 2014, Wong-Brown 2015). BRCA2 c.9502-12T>G was also seen in a breast tumor, which was determined to have characteristics similar to BRCA2-associated tumors (Joosse 2012). This variant was observed at an allele frequency of 0.02% (28/126,428) in individuals of European ancestry in large population cohorts (Lek 2016). Based on currently available evidence, it is unclear whether BRCA2 c.9502-12T>G is a pathogenic or benign variant. We consider it to be a variant of uncertain significance.
Illumina Clinical Services Laboratory,Illumina RCV000114123 SCV000383803 uncertain significance Breast-ovarian cancer, familial 2 2018-03-06 criteria provided, single submitter clinical testing This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score, this variant could not be ruled out of causing disease and therefore its association with disease required further investigation. A literature search was performed for the gene, cDNA change, and amino acid change (if applicable). No publications were found based on this search. This variant was therefore classified as a variant of unknown significance for this disease.
Department of Pathology and Laboratory Medicine,Sinai Health System RCV000160171 SCV000592291 uncertain significance not specified 2015-03-27 criteria provided, single submitter clinical testing
Integrated Genetics/Laboratory Corporation of America RCV000589086 SCV000695247 likely benign not provided 2016-08-31 criteria provided, single submitter clinical testing Variant summary: The BRCA2 c.9502-12T>G variant affects a non-conserved nucleotide, resulting in an intronic change. 5/5 in silico tools via Alamut predict a weakening effect on the RNA splicing acceptor site and 2/5 in silico tools predict a gain of a cryptic RNA splicing donor site. ESEfinder predicts gain of binding motifs for RNA splicing enhancers. However, the variant was shown through transcription assays to have little effect on splicing by two independent research groups (Houdayer_BRCA1&2_HM_2012, Acedo_HM_2015). Two other studies stated that variant of interest led to the deletion of exon 26 (Joosse_Breast Cancer Res Treat_2012 and Wong-Brown_BRCA1&2_BCRT_2015) without any experimental evidence given. This variant was found in 15/121598 control chromosomes at a frequency of 0.0001234, which does not significantly exceed maximal expected frequency of a pathogenic allele (0.0007503). This variant has been reported in multiple affected individuals without strong evidence for causality. However, a reputable database cites the variant to co-occur with another pathogenic BRCA2 variant, c.1232_1242delinsACAT (p.Ile411AsnfsX17). In addition, multiple clinical diagnostic laboratories cite the variant as "likely benign/benign" or "uncertain significance." Therefore, the variant of interest has been classified as Likely Benign.
Mendelics RCV000045842 SCV000838907 uncertain significance Hereditary breast and ovarian cancer syndrome 2018-07-02 criteria provided, single submitter clinical testing
Color Health, Inc RCV000131584 SCV000910621 benign Hereditary cancer-predisposing syndrome 2016-04-29 criteria provided, single submitter clinical testing
Mendelics RCV000114123 SCV001139267 uncertain significance Breast-ovarian cancer, familial 2 2019-05-28 criteria provided, single submitter clinical testing
Illumina Clinical Services Laboratory,Illumina RCV001110141 SCV001267540 uncertain significance Fanconi anemia, complementation group D1 2018-03-06 criteria provided, single submitter clinical testing This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score, this variant could not be ruled out of causing disease and therefore its association with disease required further investigation. A literature search was performed for the gene, cDNA change, and amino acid change (if applicable). No publications were found based on this search. This variant was therefore classified as a variant of unknown significance for this disease.
Breast Cancer Information Core (BIC) (BRCA2) RCV000114123 SCV000147656 benign Breast-ovarian cancer, familial 2 1999-06-21 no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.